Thousands of men diagnosed with prostate cancer in England are set to benefit from an innovative radiotherapy technique that significantly reduces treatment sessions from 20 to just five. This advanced method, known as stereotactic ablative radiotherapy (SABR), promises to deliver more effective targeting of cancer cells while minimising side effects, marking a substantial shift in prostate cancer care.
A New Era for Prostate Cancer Treatment
SABR has been used successfully for various types of cancer, including lung and brain tumours, but this will be the first time it is available to patients with low- and intermediate-risk prostate cancer outside of clinical trials. Each year, around 55,000 men are diagnosed with prostate cancer in England, and approximately 17,500 of these cases fall into the low- or intermediate-risk categories. Experts estimate that about 3,500 men may opt for this new treatment option, as many with low-risk prostate cancer choose active monitoring rather than immediate intervention due to the slow-growing nature of their condition.
NHS England has announced that all 48 radiotherapy centres across the country are expected to begin offering this cutting-edge treatment within weeks, a development that has been met with enthusiasm from medical professionals and patients alike.
Expert Insight into SABR’s Benefits
Professor Peter Johnson, the National Clinical Director for Cancer, highlighted the significance of this advancement. He explained that the precision of SABR allows for a powerful beam of radiotherapy to be directed specifically at the cancer, thereby limiting damage to surrounding healthy tissue. “The fact it can be delivered in 15 fewer doses will help men get back to living their lives far more quickly,” he stated.
This focused approach not only enhances treatment efficacy but also alleviates the physical and emotional burden associated with lengthy treatment regimens. Patients can expect a more streamlined path to recovery, allowing them to resume their daily activities sooner.
Patient Experiences with SABR
One patient currently involved in the trials is 70-year-old Edwin Lambert from Suffolk. After being diagnosed with prostate cancer in January 2025, he began hormone therapy, which came with several side effects, including mood swings and fatigue. Edwin then underwent the new SABR treatment, which targeted both his prostate and surrounding lymph nodes. Reflecting on his experience, he noted that the treatment was “easier to deal with” compared to traditional radiotherapy, which he observed left other patients looking “dreadful” due to the cumulative effects of multiple sessions.
He reported that while he experienced an increased need to urinate during and shortly after treatment, he was able to return to his normal activities, including participating in an archaeological dig he had long awaited, within just five weeks. “This treatment was an absolute godsend,” Edwin remarked, underscoring the positive impact of SABR on his quality of life.
The Future of Prostate Cancer Treatment
The introduction of SABR is seen as a monumental step forward in the fight against prostate cancer. Amy Rylance from Prostate Cancer UK expressed her optimism, stating, “It’s wonderful news that thousands of men in England will now have access to this revolutionary targeted radiotherapy.” She emphasised how this advancement will significantly alleviate the strain that cancer places on patients and their families, and the charity is hopeful that further trials will extend the availability of SABR to high-risk prostate cancer patients in the future.
Why it Matters
The rollout of SABR represents a transformative leap in prostate cancer treatment, enhancing the lives of countless men by reducing the number of necessary treatment sessions while improving overall outcomes. This development not only reflects a commitment to advancing cancer care but also highlights the importance of personalised medicine in addressing patient needs. As healthcare continues to evolve, innovations like SABR pave the way for a future where cancer treatment is more effective and less burdensome, allowing patients to reclaim their lives with renewed hope.
